1 week Ago By ABMN Staff
HC Wainwright began coverage on shares of Sanara MedTech ( NASDAQ:SMTI – Free Report ) in a research note issued to investors on Monday, MarketBeat.com reports. The firm issued a buy rating and a $50.
00 price target on the stock. Sanara MedTech Stock Up 1.3 % Shares of Sanara MedTech stock opened at $34.
11 on Monday. The company has a current ratio of 2.23, a quick ratio of 2.
02 and a debt-to-equity ratio of 0.76. Sanara MedTech has a 12-month low of $26.
00 and a 12-month high of $43.25. The company has a market cap of $298.
16 million, a P/E ratio of -34.45 and a beta of 1.57.
The company’s fifty day simple moving average is $34.58 and its two-hundred day simple moving average is $32.15.
Sanara MedTech ( NASDAQ:SMTI – Get Free Report ) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.
62) by $0.28. Sanara MedTech had a negative net margin of 10.
71% and a negative return on equity of 19.86%. The company had revenue of $21.
67 million for the quarter. During the same quarter in the prior year, the firm earned ($0.13) EPS.
Research analysts anticipate that Sanara MedTech will post -1.42 EPS for the current year. Institutional Inflows and Outflows About Sanara MedTech ( Get Free Report ) Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States.
The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Featured Stories Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter .
.
